Literature DB >> 13514499

A controlled trial of methyl phenidate (ritalin) in the treatment of depressive states.

A A ROBIN, S WISEBERG.   

Abstract

Entities:  

Keywords:  DEPRESSION/therapy; METHYLPHENIDYLACETATE/therapeutic use

Mesh：

Substances：

Year:  1958        PMID： 13514499      PMCID： PMC497294          DOI： 10.1136/jnnp.21.1.55

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  [Treatment of depressive states with a new central stimulant].

Authors:  W GELLER
Journal:  Medizinische       Date:  1955-04-16

2.  Treatment of reserpine-induced depression with a new analeptic: phenidylate.

Authors:  J T FERGUSON
Journal:  Ann N Y Acad Sci       Date:  1955-04-15       Impact factor: 5.691

3.  Reserpine in the treatment of anxious and depressed patients.

Authors:  D L DAVIES; M SHEPHERD
Journal:  Lancet       Date:  1955-07-16       Impact factor: 79.321

4.  [Psychological effects of a new central stimulant].

Authors:  R HEISS; H BECKER; H HILTMANN; I HONSBERG
Journal:  Medizinische       Date:  1956-02-18

5.  [Ritalin, a new synthetic compound with specific analeptic components].

Authors:  R MEIER; F GROSS; J TRIPOD
Journal:  Klin Wochenschr       Date:  1954-05-15
  5 in total
  4 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

Review 2.  Psychostimulants in the treatment of depression : a review of the evidence.

Authors:  Katy Orr; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Psychostimulants in the therapy of treatment-resistant depression Review of the literature and findings from a retrospective study in 65 depressed patients.

Authors:  G Stotz; B Woggon; J Angst
Journal:  Dialogues Clin Neurosci       Date:  1999-12       Impact factor: 5.986

4.  A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.

Authors:  Cynthia Richards; Dan V Iosifescu; Rajnish Mago; Elias Sarkis; James Reynolds; Brooke Geibel; Matthew Dauphin
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.